Close
Close
People News

MediciNova Appoints Hideki Nagao to its Board of Directors

4.0
4.0 from 1 vote
Friday, November 10, 2017

LA JOLLA, Calif. - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced the appointment of Mr. Hideki Nagao to its Board of Directors.

Mr. Nagao complements the MediciNova Board with 40 years of experience in finance and corporate law with financial institutions in Japan. Mr. Nagao started his career at Development Bank of Japan and, in 2006, he accepted the position of Senior Director, Department of Corporate Finance. In 2008, Mr. Nagao moved to Sagawa Financials, Inc. where he served as Financial Director. In 2012, he became Director at Sagawa Global Logistics and, in 2013, he served as President of Sagawa Asset Max. Currently, Mr. Nagao is an auditor at Sagawa Advance-SG Systems. He previously served as a Board Member for MediciNova from 2004 - 2010. Mr. Nagao holds a degree from the Faculty of Law of Tokyo University.

"We are extremely pleased and fortunate to add an individual with such strong expertise in the financial sector to MediciNova's Board of Directors," said Yuichi Iwaki, M.D., Ph.D., MediciNova's President and Chief Executive Officer. "We believe Mr. Nagao will be a great asset to the Company and its shareholders."

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.

Source: MediciNova, Inc
4.0
4.0 from 1 vote
Free Newsletter
Trending News
Videos
by Scott Harwood
17 views
by Abidemi Uruejoma
17 views
by Scott Harwood
17 views